In a major breakthrough in cellular therapy, FDA has approved the first tumor-infiltrating lymphocyte therapy for patients with unresectable or metastatic melanoma who have received prior treatment, including with checkpoint inhibitors.
Feb. 16, 2024, is a landmark date in the history of immuno-oncology.
James S. Allan was named chair of the Foundation for Biomedical Research board of directors.
More than a decade ago, Glenn Begley and Lee Ellis published a paper with astounding findings: of 53 “landmark” studies, only six, or 11%, were reproducible, even with the same reagents and the same protocols—and even, sometimes, in the same laboratory—as the original study.
Over 50 research papers that list top leaders of Dana-Farber Cancer Institute among authors are implicated in an investigation of allegations of data manipulation.
The American Association for Cancer Research has elected the 2023 class of fellows of the AACR Academy.
Stand Up To Cancer has announced three Research Teams focused on bringing new therapies to clinical trials for the treatment of gastroesophageal cancer.
The Advanced Research Projects Agency for Health is setting up a network of partners that would enable the federal government to fund and roll out new initiatives nationwide.
A year ago, Renee Wegrzyn signed up for a very cool job. As the inaugural director of the Advanced Research Projects Agency for Health, she was to prove that the nontraditional, $2.5 billion experiment will yield the kind of high impact its high-risk investment model promises. Since Wegrzyn joined the agency in October 2022, ARPA-H has […]
By the end of World War I, the use of chemical weapons had resulted in over one million casualties on both sides, including many disabled and wounded. Through a series of unintended events, these chemical weapons set in motion discoveries that led to the development of chemotherapy.
